SPRO Spero Therapeutics, Inc.
Spero Therapeutics, Inc. (SPRO) is expected to report earnings on February 11, 2027, after the market close. The consensus earnings estimate is a loss of $0.12 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -13.3% since its last earnings release on November 12, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Spero Therapeutics, Inc.
pero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.
Sector
Healthcare
Charts powered in part by Lightweight Charts™ by TradingView.